Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease

✍ Scribed by Carsten Saft; Jochen Zange; Jürgen Andrich; Klaus Müller; Katrin Lindenberg; Bernhard Landwehrmeyer; Matthias Vorgerd; Peter H. Kraus; Horst Przuntek; Ludger Schöls

• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: English
• Weight: 110 KB
• Volume: 20
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/mds.20373

✦ Synopsis

Abstract

Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by a CAG repeat expansion in the IT‐15 gene; however, it remains unknown how the mutation leads to selective neurodegeneration. Several lines of evidence suggest impaired mitochondrial function as a component of the neurodegenerative process in HD. We assessed energy metabolism in the skeletal muscle of 15 HD patients and 12 asymptomatic mutation carriers in vivo using 31P magnetic resonance spectroscopy. Phosphocreatine recovery after exercise is a direct measure of ATP synthesis and was slowed significantly in HD patients and mutation carriers in comparison to age‐ and gender‐matched healthy controls. We found that oxidative function is impaired to a similar extent in manifest HD patients and asymptomatic mutation carriers. Our findings suggest that mitochondrial dysfunction is an early and persistent component of the pathophysiology of HD. © 2004 Movement Disorder Society